148 related articles for article (PubMed ID: 11436701)
1. [Pharmacokinetic variability of oxcarbazepine in epileptic patients].
Viola MS; Bercellini MA; Saidón P; Rubio MC
Medicina (B Aires); 2000; 60(6):914-8. PubMed ID: 11436701
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.
Rodrigues C; Chiron C; Rey E; Dulac O; Comets E; Pons G; Jullien V
Br J Clin Pharmacol; 2017 Dec; 83(12):2695-2708. PubMed ID: 28771787
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of oral loading of oxcarbazepine suspension in selected patients with epilepsy.
Kim DW; Gu N; Lee H; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Na HJ; Lee SK
Int J Clin Pharmacol Ther; 2013 Oct; 51(10):780-6. PubMed ID: 23849326
[TBL] [Abstract][Full Text] [Related]
4. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance.
Baruzzi A; Albani F; Riva R
Epilepsia; 1994; 35 Suppl 3():S14-9. PubMed ID: 8156974
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology and pharmacokinetics of oxcarbazepine.
Lloyd P; Flesch G; Dieterle W
Epilepsia; 1994; 35 Suppl 3():S10-3. PubMed ID: 8156973
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicities.
Sugiyama I; Bouillon T; Yamaguchi M; Suzuki H; Hirota T; Fink M
Drug Metab Pharmacokinet; 2015 Apr; 30(2):160-7. PubMed ID: 25989891
[TBL] [Abstract][Full Text] [Related]
7. Fluctuations of 10-hydroxy-carbazepine during the day in epileptic patients.
May TW; Rambeck B; Sälke-Kellermann A
Acta Neurol Scand; 1996 Jun; 93(6):393-7. PubMed ID: 8836299
[TBL] [Abstract][Full Text] [Related]
8. Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.
Lu Y; Fang Y; Wu X; Ma C; Wang Y; Xu L
Eur J Clin Pharmacol; 2017 Mar; 73(3):307-315. PubMed ID: 27900402
[TBL] [Abstract][Full Text] [Related]
9. Saliva and Plasma Monohydroxycarbamazepine Concentrations in Pediatric Patients With Epilepsy.
Li RR; Sheng XY; Ma LY; Yao HX; Cai LX; Chen CY; Zhu SN; Zhou Y; Wu Y; Cui YM
Ther Drug Monit; 2016 Jun; 38(3):365-70. PubMed ID: 26818624
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of oxcarbazepine.
May TW; Korn-Merker E; Rambeck B
Clin Pharmacokinet; 2003; 42(12):1023-42. PubMed ID: 12959634
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy.
Yu Y; Zhang Q; Xu W; Lv C; Hao G
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):345-51. PubMed ID: 25700977
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD).
Miles MV; Tang PH; Ryan MA; Grim SA; Fakhoury TA; Strawsburg RH; DeGrauw TJ; Baumann RJ
Ther Drug Monit; 2004 Jun; 26(3):300-4. PubMed ID: 15167632
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of oxcarbazepine active metabolite in Chinese children with epilepsy.
Peng J; Zhang HN; Liu ZS; Xu H; Wang Y
Int J Clin Pharmacol Ther; 2014 Aug; 52(8):684-92. PubMed ID: 24887335
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy.
Chen CY; Zhou Y; Cui YM; Yang T; Zhao X; Wu Y
J Clin Pharm Ther; 2019 Apr; 44(2):300-311. PubMed ID: 30636182
[TBL] [Abstract][Full Text] [Related]
15. Oxcarbazepine: clinical development program.
Schwabe S
Epilepsia; 1994; 35 Suppl 5():S51-3. PubMed ID: 8039472
[TBL] [Abstract][Full Text] [Related]
16. Parent drug and/or metabolite? Which of them is most appropriate to establish bioequivalence of two oral oxcarbazepine formulations in healthy volunteers?
Di Girolamo G; Opezzo JA; Schere D; Gonzalez CD; Moncalvo JJ
Expert Opin Pharmacother; 2007 Jul; 8(10):1415-23. PubMed ID: 17661724
[TBL] [Abstract][Full Text] [Related]
17. Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy.
Striano S; Striano P; Di Nocera P; Italiano D; Fasiello C; Ruosi P; Bilo L; Pisani F
Epilepsy Res; 2006 May; 69(2):170-6. PubMed ID: 16515857
[TBL] [Abstract][Full Text] [Related]
18. Transplacental passage of oxcarbazepine and its metabolites in vivo.
Myllynen P; Pienimäki P; Jouppila P; Vähäkangas K
Epilepsia; 2001 Nov; 42(11):1482-5. PubMed ID: 11879354
[TBL] [Abstract][Full Text] [Related]
19. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium.
Mazzucchelli I; Onat FY; Ozkara C; Atakli D; Specchio LM; Neve AL; Gatti G; Perucca E
Epilepsia; 2006 Mar; 47(3):504-9. PubMed ID: 16529613
[TBL] [Abstract][Full Text] [Related]
20. Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs.
Volosov A; Sintov A; Bialer M
Ther Drug Monit; 1999 Apr; 21(2):219-23. PubMed ID: 10217343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
